Table 1 Characteristics of Patients with NPC in the Training and Validation Cohorts
Characteristic | Entire cohort | Training cohort | Validation cohort | P-value |
|---|---|---|---|---|
(n = 120) | (n = 80) | (n = 40) | ||
Age (years) | Â | Â | Â | 0.898 |
  Mean (SD) | 54.5 (12.6) | 54.8 (12.8) | 53.7 (12.4) |  |
  Median [Min, Max] | 55 [23, 81] | 55 [23, 81] | 55 [25, 76] |  |
Gender | Â | Â | Â | 0.456 |
  Male | 94 (78.3%) | 60 (75.0%) | 34 (85.0%) |  |
  Female | 26 (21.7%) | 20 (25.0%) | 6 (15.0%) |  |
Smoking | Â | Â | Â | 0.921 |
  No | 78 (65.0%) | 51 (63.8%) | 27 (67.5%) |  |
  Yes | 42 (35.0%) | 29 (36.3%) | 13 (32.5%) |  |
Drinking | Â | Â | Â | 0.700 |
  No | 84 (70.0%) | 54 (67.5%) | 30 (75.0%) |  |
  Yes | 36 (30.0%) | 26 (32.5%) | 10 (25.0%) |  |
WHO pathologic typea | Â | Â | Â | 0.861 |
  Type I | 3 (2.5%) | 2 (2.5%) | 1 (2.5%) |  |
  Type II | 49 (40.8%) | 34 (42.5%) | 15 (37.5%) |  |
  Type III | 68 (56.7%) | 44 (55.0%) | 24 (60.0%) |  |
Pre-treatment T stage | Â | Â | Â | 0.984 |
  T1 | 23 (19.2%) | 14 (17.5%) | 9 (22.5%) |  |
  T2 | 26 (21.7%) | 19 (23.8%) | 7 (17.5%) |  |
  T3 | 57 (47.5%) | 37 (46.3%) | 20 (50.0%) |  |
  T4a | 14 (11.7%) | 10 (12.5%) | 4 (10.0%) |  |
Pre-treatment N stage | Â | Â | Â | 0.879 |
  N0 | 13 (10.8%) | 10 (12.5%) | 3 (7.5%) |  |
  N1 | 31 (25.8%) | 18 (22.5%) | 13 (32.5%) |  |
  N2 | 70 (58.3%) | 47 (58.8%) | 23 (57.5%) |  |
  N3 | 6 (5.0%) | 5 (6.3%) | 1 (2.5%) |  |
Overall stage | Â | Â | Â | 0.988 |
  II | 19 (15.8%) | 12 (15.0%) | 7 (17.5%) |  |
  III | 80 (66.7%) | 53 (66.3%) | 27 (67.5%) |  |
  IVa | 21 (17.5%) | 15 (18.8%) | 6 (15.0%) |  |
Pre-treatment WBC (10^12/L) | Â | Â | Â | 0.375 |
  Mean (SD) | 6.64 (2.11) | 6.45 (2.07) | 7.03 (2.16) |  |
  Median [Min, Max] | 6.12 [2.23, 12.8] | 5.99 [2.23, 12.8] | 6.62 [2.84, 11.9] |  |
Pre-treatment NEUT (10^9/L) | Â | Â | Â | 0.265 |
  Mean (SD) | 4.24 (1.80) | 4.05 (1.74) | 4.62 (1.88) |  |
  Median [Min, Max] | 3.77 [0.70, 9.66] | 3.48 [0.98, 9.44] | 4.01 [0.70, 9.66] |  |
Pre-treatment PLT (10^9/L) | Â | Â | Â | 0.853 |
  Mean (SD) | 246 (90.8) | 250 (99.4) | 240 (71.1) |  |
  Median [Min, Max] | 236 [62, 724] | 235 [62, 724] | 240 [90, 459] |  |
Pre-treatment HGB (g/L) | Â | Â | Â | 0.337 |
  Mean (SD) | 141 (14.7) | 139 (14.8) | 143 (14.1) |  |
  Median [Min, Max] | 142 [96, 182] | 139 [96, 182] | 144 [114, 170] |  |
Pre-treatment CEA (ug/L) | Â | Â | Â | 0.242 |
  Mean (SD) | 2.29 (1.41) | 2.13 (1.29) | 2.59 (1.61) |  |
  Median [Min, Max] | 1.9 [0.5, 7.2] | 1.8 [0.5, 6.2] | 2.1 [0.8, 7.2] |  |
Progression-free survival (months) | Â | Â | Â | 0.944 |
  Mean (SD) | 29.9 (11.0) | 30.1 (11.0) | 29.4 (11.2) |  |
  Median [Min, Max] | 30.7 [7.0, 46.1] | 32.6 [7.0, 46.1] | 30.4 [7.0, 43.9] |  |
Follow-up time (months) | Â | Â | Â | 0.889 |
  Mean (SD) | 37.1 (8.92) | 37.4 (9.19) | 36.5 (8.43) |  |
  Median [Min, Max] | 37.9 [12.4, 53.6] | 38.4 [12.4, 53.6] | 37.4 [18.1, 48.4] |  |
Survival status | Â | Â | Â | 0.954 |
  No | 92 (76.7%) | 62 (77.5%) | 30 (75.0%) |  |
  Yes | 28 (23.3%) | 18 (22.5%) | 10 (25.0%) |  |
Progress | Â | Â | Â | 0.823 |
  No | 92 (76.7%) | 62 (77.5%) | 30 (75.0%) |  |
  Distant metastases | 18 (15.0%) | 13 (16.3%) | 5 (12.5%) |  |
  Locoregional relapses | 10 (8.3%) | 5 (6.3%) | 5 (12.5%) |  |